ClinicalTrials.gg
Active, not recruitingNCT07937514Updated Nov 16, 2026

Specimen Integrity in Laparoscopic Appendectomy

An interventional study of Specimen extraction through a 10 mm trocar and Specimen extraction through a 12 mm trocar in Appendicitis Acute, sponsored by Sezgin Topuz. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Sezgin Topuz · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2026, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Appendicitis with a site in Turkey — 10 open to participants now, 12 under way, none of them phase 3. Appendicitis · Turkey.

Planned enrollment
4th of 25
300 · median 100
Started
2026
with 8 others
No phase
23 of 45
6 open now
Primary completion
2027-01
later than 6 of 11 live
Registered
45th of 45
by date

Among the 45 studies in Appendicitis with a site in Turkey, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 45th registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

10 of the 45 studies in Appendicitis with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Appendicitis with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether the size of the port (trocar) used to remove the appendix during laparoscopic appendectomy affects whether the appendix is removed intact. The study includes adults (18 years and older) who undergo laparoscopic surgery for acute appendicitis.

The main question it aims to answer is:

- Does removing the appendix through a 12 mm trocar, compared with a 10 mm trocar, reduce damage (tearing or fragmentation) to the removed appendix?

Keeping the appendix intact is important because cancer is sometimes found unexpectedly in removed appendices, and a damaged specimen can make the pathology assessment and further treatment decisions difficult.

Researchers will also compare the two groups for operation time, length of hospital stay, pain after surgery, wound and abdominal infections, bleeding, and hernia at the port site.

Participants will:

  • Be randomly assigned to one of two groups: the appendix will be removed through either a 10 mm or a 12 mm trocar during standard laparoscopic appendectomy
  • Rate their pain after surgery using a visual analog scale
  • Be followed for complications after surgery
Read the detailed description

Background and rationale:

Laparoscopic appendectomy, first described by Semm in 1983, has become the standard treatment for acute appendicitis in adults. Its proven advantages include lower wound infection rates, faster recovery, and shorter hospital stay. One of the main benefits of laparoscopic surgery is the use of small incisions; however, small incisions can make specimen extraction difficult and may compromise the integrity of the pathological specimen. Although the appendix is a small organ, it is usually extracted through a 10 mm trocar, which occasionally leads to tearing or fragmentation of the specimen. Malignancies such as neuroendocrine tumors and mucinous neoplasms are found incidentally in appendectomy specimens, and a disrupted specimen may complicate pathological staging, margin assessment, and decisions about further treatment. To our knowledge, no prospective randomized controlled trial has compared the effect of trocar size on specimen integrity in laparoscopic appendectomy.

Study design:

This is a single-center, prospective, randomized controlled trial conducted at the Department of General Surgery, Kahramanmaraş Sütçü İmam University Faculty of Medicine. After approval by the institutional ethics committee and written informed consent, patients diagnosed with acute appendicitis and scheduled for laparoscopic appendectomy will be randomly allocated in a 1:1 ratio to two groups. Demographic data (age, sex, comorbidities, height, weight, body mass index) will be recorded.

Interventions:

All operations will be performed using a standard laparoscopic technique with 5 mm, 10 mm, and 12 mm trocars. In Group 1, the appendix will be extracted through a 10 mm trocar; in Group 2, it will be extracted through a 12 mm trocar. All other steps of the operation will follow routine practice. Specimens will be evaluated by the pathology department, and integrity will be classified as intact or disrupted.

Sample size:

Sample size was calculated with G*Power 3.1 (Fisher's exact test, two-tailed). Assuming a specimen disruption rate of 15% with a 10 mm trocar (based on pilot data) and 5% with a 12 mm trocar, with alpha = 0.05 and power = 0.80, 150 patients per group (300 in total) are required.

Statistical analysis:

Normality of continuous variables will be assessed with the Shapiro-Wilk test. Categorical variables, including specimen integrity, will be compared with the chi-square or Fisher's exact test. Continuous variables will be compared with the independent samples t-test or the Mann-Whitney U test, as appropriate. A p value \< 0.05 will be considered statistically significant.

03

Conditions studied

  • Appendicitis Acute

Browse trials for

Keywords

  • Laparoscopic Appendectomy
  • Trocar Size
  • Specimen Integrity
  • Specimen Extraction
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of acute appendicitis
  • Undergoing laparoscopic appendectomy
  • Written

Exclusion criteria

Exclusion Criteria:

  • Appendiceal mass (plastron appendicitis)
  • Preoperative diagnosis or suspicion of appendiceal
  • Conversion to open surgery
  • Pregnancy
  • Refusal to participate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    10 mm Trocar Group

    Laparoscopic appendectomy with extraction of the appendix through a 10 mm trocar.

    Procedure: Specimen extraction through a 10 mm trocar

  • Experimental
    12 mm Trocar Group

    Laparoscopic appendectomy with extraction of the appendix through a 12 mm trocar.

    Procedure: Specimen extraction through a 12 mm trocar

Interventions

  • ProcedureSpecimen extraction through a 10 mm trocar

    During standard laparoscopic appendectomy, the appendix is removed from the abdominal cavity through a 10 mm trocar, which is the routine practice in our clinic.

  • ProcedureSpecimen extraction through a 12 mm trocar

    During standard laparoscopic appendectomy, the appendix is removed from the abdominal cavity through a 12 mm trocar instead of the routinely used 10 mm trocar. All other steps of the operation are identical.

06

What researchers measure

Primary outcomes

  1. Rate of Disrupted Appendectomy Specimens

    Integrity of the extracted appendix as assessed by the pathologist on macroscopic examination, classified as intact or disrupted (torn, fragmented, or perforated during extraction). The proportion of disrupted specimens will be compared between the 10 mm and 12 mm trocar groups

    Time frame: At pathological examination, within 14 days after surgery

Secondary outcomes

  1. Operative Time

    Time from skin incision to skin closure, in minutes.

    Time frame: Intraoperative

  2. Postoperative Pain Score

    Pain intensity measured with the Visual Analog Scale (0 = no pain, 10 = worst

    Time frame: At 6, 24, and 48 hours after surgery

  3. Length of Hospital Stay

    Number of days from surgery to discharge.

    Time frame: From surgery to discharge, up to 30 days

  4. Rate of Surgical Site Infection

    Description: Superficial or deep incisional infection and intra-abdominal infection (abscess).

    Time frame: Within 30 days after surgery

  5. Rate of Postoperative Bleeding

    Bleeding from trocar sites or intra-abdominal bleeding requiring intervention.

    Time frame: Within 30 days after surgery

  6. Rate of Trocar Site Hernia

    Incisional hernia at the specimen extraction trocar site, diagnosed by physical examination.

    Time frame: 6 months after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data underlying the results reported in the publication will be available upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Of 92 non-industry interventional studies with no phase under Appendicitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 5 months is below that.

Counting every sponsor, half of 94 studies reached it within 19 months; a quarter within 10 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 5, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937514
Lead sponsor
Sezgin Topuz
Responsible party
Sezgin Topuz (Assistant Professor, Kahramanmaras Sutcu Imam University) — Sponsor-investigator
First posted
Nov 16, 2026
Start date
Aug 1, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion